GPs to offer two new tests for early endometriosis detection

A consortium of medical researchers and biotech firms announced the development of a novel diagnostic platform that could dramatically shorten the time patients wait for a definitive diagnosis. The technology, which combines advanced genomic sequencing with artificial‑intelligence analysis, is being positioned as a potential “game‑changer” for conditions that currently require extensive testing and specialist referral. Clinical trials are slated to begin later this year, with regulatory submissions planned for early next year.

Experts say the new platform could reduce the typical nine‑year or longer diagnostic odyssey that many patients with rare or complex diseases endure. By delivering comprehensive molecular insights from a single blood sample, the system aims to streamline the identification of underlying pathologies and enable earlier therapeutic intervention. If the trials confirm the anticipated performance, the tool may reshape diagnostic pathways, lessen the burden on specialist services, and improve outcomes for patients awaiting answers.